Phase II study of roquinimex in myelodysplastic syndrome.

  title={Phase II study of roquinimex in myelodysplastic syndrome.},
  author={Craig S. Rosenfeld and Zella R. Zeigler and Richard K. Shadduck and B. Nilsson},
  journal={American journal of clinical oncology},
  volume={20 2},
  • Craig S. Rosenfeld, Zella R. Zeigler, +1 author B. Nilsson
  • Published in
    American journal of clinical…
  • Medicine
  • A Phase II clinical trial was undertaken using roquinimex (Linomide) in patients with myelodysplastic syndromes (MDS). Roquinimex is an orally active drug with immunostimulating activities demonstrated in vitro and clinically. Seventeen patients with MDS were enrolled in the study. Eligibility was limited to cytopenic patients with <20% marrow blasts. The drug was given orally twice weekly for 12 weeks with frequent monitoring of clinical, hematologic, and immunologic parameters. An increase in… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv